Lv2
140 积分 2025-12-31 加入
Imlunestrant: First Approval
2小时前
已完结
Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
3个月前
已完结
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
3个月前
已完结
Plozasiran and Apolipoprotein C-III Inhibition
3个月前
已完结
EFFECT OF PLOZASIRAN TARGETING APOC3 ON LIPOPROTEIN PARTICLE NUMBER AND SIZE MEASURED BY NMR IN PATIENTS WITH HYPERTRIGLYCERIDEMIA (HTG)
3个月前
已完结
siRNA therapy lowers triglycerides in patients with rare condition
3个月前
已关闭
RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia
3个月前
已完结
Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause
3个月前
已完结
Elinzanetant: First Approval
3个月前
已关闭
Paltusotine: First Approval
3个月前
已完结
皖公网安备34019202002308
